ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy is the analysis of tumour components in bodily fluids and is increasingly considered a complementary approach to conventional diagnostics. Although tissue biopsy is the gold standard in clinical diagnostics, this approach is invasive, spatially restricted, and often difficult to perform repeatedly. Liquid biopsy is a minimally invasive approach for molecular analysis of tumours using circulating tumour DNA, cells, and extracellular vesicles, including exosomes. Although significant progress in this field has been made, a comprehensive synthesis of the biological basis, analytical methods, and clinical utility of these circulating markers still seems fragmented, with considerable methodological heterogeneity hindering standardised clinical use. This, in turn, underscores the need to understand the appropriate approach to the clinical utility of liquid biopsy. This review article is a concise and comprehensive synthesis of important liquid biopsy markers, a review of detection methods and their utility in cancer management, and an examination of the methodological limitations of this approach, including sensitivity, standardisation, and interpretation. This review article consolidates current evidence and highlights the importance of liquid biopsy and its utility for disease monitoring and precision oncology-based therapeutic decisions.
Indexed as
Identifiers
41999549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.